Scarica l'app Stockscreener
112.86
1.27%
1.42
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PTGX Giù?
Forum
Previsione
Precedente Chiudi:
$111.44
Aprire:
$112.88
Volume 24 ore:
1.52M
Relative Volume:
2.11
Capitalizzazione di mercato:
$7.26B
Reddito:
$74.06M
Utile/perdita netta:
$-114.71M
Rapporto P/E:
-62.56
EPS:
-1.8039
Flusso di cassa netto:
$-117.90M
1 W Prestazione:
+2.80%
1M Prestazione:
+12.03%
6M Prestazione:
+31.55%
1 anno Prestazione:
+109.31%
Intervallo 1D:
$111.17
$114.48
Intervallo di 1 settimana:
$108.53
$114.48
Portata 52W:
$49.38
$114.48
Protagonist Therapeutics Inc Stock (PTGX) Company Profile
Nome
Protagonist Therapeutics Inc
Settore
Industria
Telefono
(510) 474-0170
Indirizzo
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
Compare PTGX vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PTGX
Protagonist Therapeutics Inc
|
112.86 | 7.26B | 74.06M | -114.71M | -117.90M | -1.8039 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-17 | Iniziato | Barclays | Overweight |
| 2025-09-12 | Iniziato | Leerink Partners | Outperform |
| 2025-06-17 | Iniziato | Citigroup | Buy |
| 2024-12-06 | Iniziato | BMO Capital Markets | Outperform |
| 2024-12-06 | Iniziato | Goldman | Neutral |
| 2024-11-05 | Iniziato | Wedbush | Outperform |
| 2024-09-24 | Iniziato | TD Cowen | Buy |
| 2024-09-09 | Iniziato | Truist | Buy |
| 2023-10-30 | Iniziato | CapitalOne | Overweight |
| 2023-05-25 | Ripresa | Jefferies | Buy |
| 2022-08-25 | Iniziato | JMP Securities | Mkt Outperform |
| 2022-02-11 | Iniziato | BTIG Research | Buy |
| 2021-10-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-10-11 | Aggiornamento | Northland Capital | Market Perform → Outperform |
| 2021-09-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-05-24 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-05-24 | Iniziato | Northland Capital | Outperform |
| 2021-01-06 | Iniziato | JP Morgan | Overweight |
| 2020-12-16 | Iniziato | Piper Sandler | Overweight |
| 2020-09-18 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-15 | Iniziato | Jefferies | Buy |
| 2020-05-18 | Reiterato | H.C. Wainwright | Buy |
| 2019-07-08 | Iniziato | H.C. Wainwright | Buy |
| 2019-05-09 | Aggiornamento | Stifel | Hold → Buy |
| 2018-12-06 | Iniziato | Nomura | Buy |
| 2018-01-29 | Iniziato | Stifel | Buy |
| 2017-07-21 | Iniziato | BTIG Research | Buy |
Mostra tutto
Protagonist Therapeutics Inc Borsa (PTGX) Ultime notizie
Protagonist Therapeutics stock hits all-time high at 113.75 USD By Investing.com - Investing.com India
Protagonist Therapeutics Adopts 2026 Equity Incentive Plan Following Shareholder Approval - Minichart
Protagonist Therapeutics (PTGX) OKs 2026 equity plan and re-elects directors at annual meeting - Stock Titan
Top Generate Biomedicines (GENB) Competitors 2026 - MarketBeat
Protagonist Therapeutics stock hits all-time high at 113.75 USD - Investing.com
Protagonist Therapeutics Inc (PTGX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Protagonist Therapeutics Inc (PTGX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Protagonist Therapeutics Inc (PTGX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Protagonist Therapeutics Inc (PTGX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Protagonist Therapeutics Inc (PTGX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Protagonist Therapeutics Inc (PTGX) Institutional Confidence - TradingKey
Protagonist Therapeutics Inc - TradingKey
Protagonist Therapeutics Inc (PTGX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
PTGX: All proposals, including director elections and equity plan, were approved at the AGM - TradingView
Understanding Momentum Shifts in (PTGX) - Stock Traders Daily
Protagonist Therapeutics Inc (PTGX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Protagonist Therapeutics Reports Granting of Inducement Awards - ACCESS Newswire
New hires at Protagonist receive stock options at $112.46 - Stock Titan
Wall Street Says Johnson And Johnson’s FDA-Approved Psoriasis Drug Should Create 'Significant Value’ For Protagonist Therapeutics - Stocktwits
NEXTBio Capital Management LP Takes Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Top Damora Therapeutics, Inc. Common Stock (DMRA) Competitors 2026 - MarketBeat
Protagonist Therapeutics: A Royalty-Driven Biotech With Two Shots On Goal (NASDAQ:PTGX) - Seeking Alpha
Keystone Investors PTE Ltd. Buys Shares of 26,390 Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) Shows Technical Strength and High Growth Momentum - ChartMill
Silence Therapeutics Stock Rises On Positive Blood Cancer Drug Data - Benzinga
Protagonist Therapeutics director Waddill sells $969,120 in shares By Investing.com - Investing.com Canada
Protagonist Therapeutics director Waddill sells $969,120 in shares - Investing.com
Protagonist Therapeutics (NASDAQ: PTGX) director exercises 9,000 options, sells 9,000 shares under 10b5-1 plan - Stock Titan
PTGX Stock Quote Price and Forecast - CNN
571,825 Shares in Protagonist Therapeutics, Inc. $PTGX Bought by Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. - MarketBeat
Protagonist Therapeutics stock hits all-time high at 107.86 USD - Investing.com India
Protagonist Therapeutics stock hits all-time high at 107.86 USD By Investing.com - Investing.com Nigeria
PTGX (NASDAQ) insider 10b5-1 sale of 9,000 shares; option exercise noted - Stock Titan
PTGX: Icotyde's strong launch and a robust pipeline drive growth, with Rusfertide approval expected soon - TradingView
Transcript : Protagonist Therapeutics, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-10-2026 09 - marketscreener.com
Protagonist Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Clearbridge Investments LLC Buys Shares of 489,842 Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Therapeutics Jumps 6.3% Amid Sector-Wide Rally - AlphaStreet
BNP Paribas Financial Markets Has $8.54 Million Stock Holdings in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in September 2025 - Salinas Californian
Protagonist Therapeutics, Inc. - MLQ.ai
Protagonist Therapeutics stock rallies nearly 7% in a week: Here's why - MSN
Assessing Protagonist Therapeutics (PTGX) Valuation After Positive Rusfertide Data And Icotyde Approval News - Sahm
Avoiding Lag: Real-Time Signals in (PTGX) Movement - Stock Traders Daily
Geode Capital Management LLC Boosts Stock Holdings in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Therapeutics Jumps 6.1% Amid Sector-Wide Rally - AlphaStreet
PTGX: Robust royalties, pipeline progress, and share buyback plans drive strong growth outlook - TradingView
Protagonist Therapeutics director Waddill sells $896,760 in common stock By Investing.com - Investing.com South Africa
Protagonist Therapeutics director Waddill sells $896,760 in common stock - Investing.com
Director at Protagonist Therapeutics (PTGX) sells shares after exercising options - Stock Titan
Protagonist Therapeutics to Present Phase 3 VERIFY and Long-Term Rusfertide Data at the 2026 European Hematology Association Congress - ACCESS Newswire
Protagonist Therapeutics Inc Azioni (PTGX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.74%
1.44%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):